An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

GEMO Study Collaborators, HEBON

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.

Original languageEnglish
Article number61
JournalBreast Cancer Research
Volume17
Issue number1
DOIs
StatePublished - 25 Apr 2015
Externally publishedYes

Funding

FundersFunder number
Hungarian Research and Technological Innovation Fund
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Universiteit Gent
Samuel Oschin Comprehensive Cancer Institute
Office of the Director
National Breast Cancer Foundation
Centro Nacional de Investigaciones Oncológicas
Mayo Clinic
Spanish Association
Ohio State University Comprehensive Cancer Center
International Hereditary Cancer Center
Morris and Horowitz Families
Thematic Network Cooperative Research in Cancer
Breast Cancer Research Foundation
Ligue Contre le Cancer
Instituto de Salud Carlos III
Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study
Ohio State University
Cancer Association of South Africa
Istituto Oncologico Veneto
Istituto Nazionale dei Tumori
Icelandic Association
CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella
University of California, Los Angeles Jonsson Comprehensive Cancer Center Foundation
Cedars-Sinai Medical Center
SLN
National Israeli Cancer Control Center
Centre National de la Recherche Scientifique
Clalit Health Services in Israel
Neye Foundation
National Institutes of Health
Center for Molecular Medicine Cologne
GC-HBOC
European Commission
Ting Tsung and Wei Fong Chao Family Foundation
Associazione Italiana per la Ricerca sul Cancro
Jeju National University Hospital
BMBSA
Dr Ellen Li Charitable Foundation
Instituto Português de Oncologia do Porto
Fundación Mutua Madrileña
Liepaja City Council
Ministero della Salute
Cancer Foundation of Western Australia
Victorian Cancer Agency
Susan G. Komen for the Cure
National Health and Medical Research Council
INT
Israeli Inherited breast cancer consortium
University of Kansas
Hereditary Cancer Research Registry
Dr. Ralph and Marian Falk Medical Research Trust
CMMC
CNIO
Beckman Research Institute, City of Hope
Helsingin ja Uudenmaan Sairaanhoitopiiri
Red Temática Investigación Cooperativa en Cáncer
Cancer Council NSW
McGill University Jewish General Hospital
State Budget of the Czech Republic
Institut Català d’Oncologia
Finnish Cancer Society
Spanish National Cancer Research Center
Landspitali University Hospital Research Fund
Interdisciplinary Health Research Internal Team Breast Cancer Susceptibility Study
European Regional Development Fund
Spanish Health Research Foundation
Cancer Australia
Instituto de Salud
Fundación Ramón Areces
Entertainment Industry Fund National Women’s Cancer Research Alliance
Sigrid Juséliuksen Säätiö
Victorian Familial
Cancer Council Queensland
Institut Català de la Salut
Basser Center for BRCA
Comprehensive Cancer Centre Netherlands and Comprehensive Centre South
National Cancer InstituteP30CA016672, U01CA113916, R01CA083855, U01CA161032, R01CA102776, P50CA116201, U01CA116167, ZIACP010144, R01CA140323, P30CA168524, R01CA142996, UM1CA164920, U10CA027469, R01CA128978, U24CA196067, RC4CA153828, R01CA176785, P30CA008748, P50CA125183, U10CA037517, U10CA101165
Universitair Ziekenhuis Gent12/00539, RD12/00369/0006
Russian Foundation for Basic Research12-04-00928, 11-04-00227, 12-04-01490
Seventh Framework Programme223175
Deutsche Krebshilfe109076
Robert and Kate Niehaus Clinical Cancer Genetics InitiativeN02-CP-11019-50, N02-CP-65504
Pomorski Uniwersytet Medyczny W SzczeciniePBZ_KBN_122/P05/2004
Federal Agency for Science and Innovation02.740.11.0780
Cancer Research UKC12292/A11174, C1287/A10118
Univerzita Karlova v PrazeUNCE204024
Canadian Institutes of Health ResearchBOF10/GOA/019
Research Council of Finland266528
Centro de Investigación Cáncer, Salamanca, SpainRTICC 06/0020/1060
Nederlandse Organisatie voor Wetenschappelijk Onderzoek110005, NWO 91109024, 184.021.007
American Cancer SocietySIOP-06-258-01-COUN
LSC10.0010.08
Ministry of Health of the Czech Republic to Masaryk Memorial Cancer InstituteMMCI 00209805
Lietuvos Mokslo TarybaLIG-07/2012
Generalitat de CatalunyaPI09/02483, PI13/00189 2009SGR290, PI10/01422, PI13/00285, ISCIIIRETIC RD06/0020/1051, PI10/00748, PI13/00189 2009SGR283
National Institute for Health ResearchC5047/A8385
RECAMOCZ.1.05/ 2.1.00/03.0101
University of PennsylvaniaR01 CA083855, R01 CA102776
Biobanking and Molecular Resource Infrastructure184.021.007/CP46
Hungarian Scientific Research FundKTIA-OTKA K-112228, KTIA-OTKA CK-80745
Istituto Toscano Tumori2011–2013
University of Kansas Cancer CenterR01 CA140323, 5U01 CA113916, P30 CA168524
CancerfondenR01 CA142996, 1U01CA161032
European Social Fund2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016
Deutsches KrebsforschungszentrumC1287/A11990
Ministère du Développement Économique, de l’Innovation et de l’ExportationPSR-SIIRI-701
Canadian Breast Cancer Research Alliance019511
COH-CCGCRNRC4CA153828
US Department of Defense Ovarian Cancer IdeaW81XWH-10-1-0341
Ministerio de Ciencia e InnovaciónFIS PI08 1120, SAF2010-20493
Dutch Cancer SocietyNKI1998-1854, NKI2004-3088, NKI2007-3756

    Fingerprint

    Dive into the research topics of 'An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers'. Together they form a unique fingerprint.

    Cite this